Literature DB >> 2896265

Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin.

S Ishikawa1, T Saito, T Kuzuya.   

Abstract

The effect of somatostatin on the stimulation of adenosine-3',5'-cyclic monophosphate (cAMP) production by arginine vasopressin (AVP) was examined in rat renal papillary collecting tubule cells in culture. The presence of phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine AVP at a concentration of 1 X 10(-10) M or higher significantly increased cellular cAMP levels in a dose-dependent manner. The stimulation by AVP of cellular cAMP production was significantly attenuated by 1 X 10(-6) M somatostatin (1 X 10(-9) M AVP, 477.5 +/- 23.0 vs. 292.4 +/- 28.5 fmol/micrograms protein per 10 min, P less than 0.01). When the cells were pretreated with pertussis toxin, pertussis toxin completely abolished the inhibitory effect of somatostatin on cellular cAMP production in response to AVP. Such an effect was obtained with a concentration of 0.1 ng/ml or higher of pertussis toxin and an incubation time of longer than an hour. The exposure of cells to 100 ng/ml pertussis toxin for two hours recovered the cellular cAMP response to 1 X 10(-9) M AVP in the presence of 1 X 10(-6) M somatostatin, the value of which 527.1 +/- 32.6 fmol/micrograms protein per 10 minutes, was a comparable level to that in response to only 1 X 10(-9) M AVP. Also, somatostatin inhibited the cellular cAMP response to glucagon and cholera toxin, but did not inhibit basal and forskolin-stimulated cAMP levels. Pertussis toxin treatment of cells completely abolished these inhibitory effects of somatostatin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896265     DOI: 10.1038/ki.1988.31

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Edwin M Spithoven; Niek F Casteleijn; Wendy A Dam; Jacob van den Born; Wouter F Tonnis; Carlo A J M Gaillard; Esther Meijer
Journal:  BMC Nephrol       Date:  2018-12-19       Impact factor: 2.388

2.  Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor.

Authors:  M Cecilia Ortiz-Capisano; Mahendranath Reddy; Mariela Mendez; Jeffrey L Garvin; William H Beierwaltes
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

3.  Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Authors:  Katharina Hopp; Cynthia J Hommerding; Xiaofang Wang; Hong Ye; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 10.121

Review 4.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

Review 5.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

6.  Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Niek F Casteleijn; Esther Meijer; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2020-08-01       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.